Background: Up to a third of prostate cancer patients fail curative treatment strategies such as surgery and radiation therapy in the form of biochemical recurrence (BCR) which can be predictive of poor outcome. Recent clinical trials have shown that men experiencing BCR might benefit from earlier intervention post-radical prostatectomy (RP). Therefore, there is an urgent need to identify earlier prognostic biomarkers which will guide clinicians in making accurate diagnosis and timely decisions on the next appropriate treatment. The objective of this study was to evaluate Serum Response Factor (SRF) protein expression following RP and to investigate its association with BCR.
Materials and Methods: SRF nuclear expression was evaluated by immunohistochemistry (IHC) in TMAs across three international radical prostatectomy cohorts for a total of 615 patients. Log-rank test and Kaplan-Meier analyses were used for BCR comparisons. Stepwise backwards elimination proportional hazard regression analysis was used to explore the significance of SRF in predicting BCR in the context of other clinical pathological variables. Area under the curve (AUC) values were generated by simulating repeated random sub-samples.
Results: Analysis of the immunohistochemical staining of benign versus cancer cores showed higher expression of nuclear SRF protein expression in cancer cores compared with benign for all the three TMAs analysed (P < 0.001, n = 615). Kaplan-Meier curves of the three TMAs combined showed that patients with higher SRF nuclear expression had a shorter time to BCR compared with patients with lower SRF expression (P < 0.001, n = 215). Together with pathological T stage T3, SRF was identified as a predictor of BCR using stepwise backwards elimination proportional hazard regression analysis (P = 0.0521). Moreover ROC curves and AUC values showed that SRF was better than T stage in predicting BCR at year 3 and 5 following radical prostatectomy, the combination of SRF and T stage had a higher AUC value than the two taken separately.
Conclusions: SRF assessment by IHC following RP could be useful in guiding clinicians to better identify patients for appropriate follow-up and timely treatment. We have demonstrated SRF clinical relevance in CRPC by immunohistochemical staining of transurethral resections of the prostate in patients who failed hormone ablation therapy with the prostate in situ. 7 In line with previous studies, 11 we have also shown a negative association between SRF nuclear positivity in bone metastases of patients who died of prostate cancer and survival from time of diagnosis and time of castration-resistance. 10 In the same cohort of patients, we also demonstrated that higher expression of SRF correlated with shorter survival in the context of docetaxel resistance. 12 The aim of this study was to assess SRF expression in RP tissues in order to explore SRF association with BCR with the remit of using SRF, alone or in combination with other markers, as a possible biomarker of BCR which can predict the development of distant metastases following RP.
| MATERIALS AND METHODS

| Tissue Microarrays (TMAs)
A total of 615 patients from three independent TMAs were assessed for this study. A summary of their clinical-pathological characteristics is shown in Sweden, using a previously described protocol. 13 From each patient, benign and malignant cores in duplicate were mounted in a total of 13 paraffin blocks. BCR was defined as a blood PSA level of at least 0.2 ng/mL with a subsequent confirmatory value. 
| Immunohistochemistry
Antigen retrieval of the deparaffinised tissue sections was performed using a PT-Link module (DAKO) at 95-99°C for 20 min in a citric acid buffer (0.01 M, pH 6.0). Slide staining was performed using an automated DAKO Link 48 according to the manufacturer instructions. Tonsil sections were used as positive controls for SRF staining. Prior to this study, the SRF antibody was subjected to western blot analysis using LNCaP cell lines which confirmed specificity for SRF (data not shown). 7 
| Immunohistochemistry scoring and statistical analysis
Some unusable cores were found in the TMAs due to the tissue cores being missing, cancer necrosis, or insufficient cancer cells.
These cores were excluded from the study. Nuclear immunoreactivity for SRF was assessed by two independent observers (MP and AF) with good agreement between the two observers. Cases for which there were discrepancies of scoring were reviewed and an agreement was found. SRF immunostaining was assessed using a nuclear score, created by multiplying each intensity level (0, no 
| SRF expression in radical prostatectomies is a predictor of BCR
In addition to exclusion of patients for technical reasons (missing tissue cores, cancer necrosis, insufficient cancer cells), patients with positive margins were also excluded from the analysis due to the fact that positive margins may be associated with BCR due to tumor cells left behind following surgery, thus confounding our analysis. We also excluded patients for whom clinical information was missing. 
| DISCUSSION
Following RP it is crucially important to monitor the risk of BCR in order to implement appropriate monitoring and timely intervene with the appropriate treatment in case of relapse. In this study, SRF nuclear expression was assessed as a biomarker for BCR which may help to FIGURE 3 SRF protein expression in benign versus cancer tissues. Columns represent average SRF nuclear score. Bar, standard deviations. Averages were compared using t test assuming equal variance stratify patients to appropriate treatments in a more timely fashion.
Using three independent TMAs of tissues from RP we showed that SRF expression was higher in cancer cores compared to benign cores, Recently two studies have identified gene-signatures associated with high-risk of relapse and metastatic prostate cancer. 17, 18 These studies used RNA platforms such as RNA-Seq 17 and gene chip microarrays 18 following RNA isolation from formalin-fixed paraffin-embedded (FFPE) material. Interestingly, some of the genes identified by these studies (LASP1, TNFRSF19, NFIB, IGFBP3, IFT57, FDPS, COL3A1, BTG2) were previously found to be de-regulated by our group, in a gene chip study comparing
LNCaP cells with their castrate-resistant subline LNCaP Abl. 6 Among these genes, three are predicted SRF transcriptional targets, namely LASP1 and NFIB included in the 22 markers of the genomic classifier discovered by Erho et al 18 and COL3A1, part of the 24 biomarker panel discovered by Long et al. 17 This strengthens the value of using TFs such as SRF as biomarkers, due to their ability to activate/repress many downstream genes which are then found de-regulated in more complex gene-signatures. In 
| CONCLUSION
While further validation of SRF as a biomarker for BCR and high-risk prostate cancer is needed, our study has highlighted the importance of SRF as a marker of disease progression in prostate cancer and its possible use as a biomarker to better stratify patients for appropriate and timely treatments following RP.
